Elacytarabine

Research use only, not for human use.

Elacytarabine (CP-4055, CP4055, ELACYT) is a fatty acid derivative of cytarabine with potential antineoplastic activity.

Elacytarabine (CP-4055, CP4055, ELACYT) is a fatty acid derivative of cytarabine with potential antineoplastic activity; CP-4055 is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, CP-4055 shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine. Chemotherapeutic Agents Phase 2 Clinical.

——

——

CP-4055 | CP4055 | ELACYT

Cell Cycle/DNA Damage

Nucleoside Antimetabolite/Analog

Nucleoside Antimetabolite/Analog

Cancer

Chemotherapeutic

188181-42-2

507.672

C27H45N3O6

>98% (HPLC)

DMSO : 125 mg/mL 246.23 mM

CCCCCCCC/C=C/CCCCCCCC(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@@H](O)[C@@H]1O)=O

[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate

(-20℃)

With Ice Pack

≥ 2 years